Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Waters

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Oncotarget|November 29, 2016
Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surfaceXiaoying Ye, King C Chan, Andrew M Waters, et al.
Science Signaling|September 28, 2017
Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodiesAndrew M Waters, Irem Ozkan-Dagliyan, Angelina V Vaseva, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerWen-Hsuan Chang, Alec J Vaughan, Addison G Stamey, et al.
NPJ Precision Oncology|May 31, 2024
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancersDaniel P Nussbaum, Colin A Martz, Andrew M Waters, et al.
Science Signaling|August 9, 2022
Functional and biological heterogeneity of KRAS<sup>Q61</sup> mutationsMinh V Huynh, G Aaron Hobbs, Antje Schaefer, et al.
Cancer Research|November 8, 2022
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic CancerCraig M Goodwin, Andrew M Waters, Jennifer E Klomp, et al.
Cancer Research|November 17, 2025
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic CancerSzu-Aun Long, Haley Todd, Grace Goodhart, et al.
Cell Reports|June 20, 2020
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan-Dagliyan, J Nathaniel Diehl, Samuel D George, et al.
Cell Reports|February 15, 2018
Differential Effector Engagement by Oncogenic KRASTina L Yuan, Arnaud Amzallag, Rachel Bagni, et al.
Cancer Research|November 5, 2021
Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and GrowthDanielle R Cook, Melissa Kang, Timothy D Martin, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Oncotarget|November 29, 2016
Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surfaceXiaoying Ye, King C Chan, Andrew M Waters, et al.
Science Signaling|September 28, 2017
Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodiesAndrew M Waters, Irem Ozkan-Dagliyan, Angelina V Vaseva, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerWen-Hsuan Chang, Alec J Vaughan, Addison G Stamey, et al.
NPJ Precision Oncology|May 31, 2024
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancersDaniel P Nussbaum, Colin A Martz, Andrew M Waters, et al.
Science Signaling|August 9, 2022
Functional and biological heterogeneity of KRAS<sup>Q61</sup> mutationsMinh V Huynh, G Aaron Hobbs, Antje Schaefer, et al.
Cancer Research|November 8, 2022
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic CancerCraig M Goodwin, Andrew M Waters, Jennifer E Klomp, et al.
Cancer Research|November 17, 2025
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic CancerSzu-Aun Long, Haley Todd, Grace Goodhart, et al.
Cell Reports|June 20, 2020
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan-Dagliyan, J Nathaniel Diehl, Samuel D George, et al.
Cell Reports|February 15, 2018
Differential Effector Engagement by Oncogenic KRASTina L Yuan, Arnaud Amzallag, Rachel Bagni, et al.
Cancer Research|November 5, 2021
Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and GrowthDanielle R Cook, Melissa Kang, Timothy D Martin, et al.
Pageof 3